BIXT (Bioxytran) 3-Year EBITDA Growth Rate: -3.40% (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Bioxytran 3-Year EBITDA Growth Rate?

Bioxytran BIXT -3.22% 3-Year EBITDA Growth Rate is -3.40% as of Jun. 2026. The stock has 4 warning signs investors should review. Among 1,129 Biotechnology companies, Bioxytran ranks worse than 73.07% on this metric.

Bioxytran's EBITDA per Share for the three months ended in Jun. 2026 was $-0.01.

During the past 3 years, the average EBITDA Per Share Growth Rate was -3.40% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was 3.20% per year. During the past 10 years, the average EBITDA Per Share Growth Rate was 34.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Bioxytran was 92.10% per year. The lowest was -227.30% per year. And the median was 36.70% per year.

Bioxytran  (OTCPK:BIXT) 3-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

Bioxytran 3-Year EBITDA Growth Rate Related Terms

BIXT vs CASIF, DCOY, PKTX: 3-Year EBITDA Growth Rate Comparison

For the Biotechnology subindustry, Bioxytran's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Bioxytran 3-Year EBITDA Growth Rate vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Bioxytran's 3-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Bioxytran's 3-Year EBITDA Growth Rate falls into.


Bioxytran 3-Year EBITDA Growth Rate Calculation

This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

What does a 3-Year EBITDA Growth Rate of -3.40% mean?
Bioxytran (BIXT) has a 3-Year EBITDA Growth Rate of -3.40% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Bioxytran and its competitors. According to the industry distribution chart, Bioxytran ranks #825 out of 1129 companies in the Biotechnology industry, placing it in the top 73.1%.
Is Bioxytran's 3-Year EBITDA Growth Rate too high?
Bioxytran's current 3-Year EBITDA Growth Rate is -3.40%. Based on the distribution chart, Bioxytran ranks #825 out of 1129 companies in the Biotechnology industry, which is below the industry midpoint.
How does Bioxytran's 3-Year EBITDA Growth Rate compare to CASIF and DCOY?
According to the Biotechnology industry distribution chart, Bioxytran ranks #825 out of 1129 companies for 3-Year EBITDA Growth Rate. This places Bioxytran in the lower half of its industry. The industry median 3-Year EBITDA Growth Rate is 14.90. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Biotechnology company?
The median 3-Year EBITDA Growth Rate among Biotechnology companies is 14.90, based on 1,129 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Bioxytran and its competitors. For the Biotechnology industry, the median 3-Year EBITDA Growth Rate is 14.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bioxytran's current 3-Year EBITDA Growth Rate is -3.40%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bioxytran stock overvalued right now?
Bioxytran (BIXT) has a current 3-Year EBITDA Growth Rate of -3.40%. The current 3-Year EBITDA Growth Rate is -3.40%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Bioxytran (BIXT), the current 3-Year EBITDA Growth Rate is -3.40% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Bioxytran Business Description

Address 75 2nd Avenue, Suite 605, Needham, MA, USA, 02494
Bioxytran Inc is a clinical stage pharmaceutical company developing platform technologies in the fields of Glycovirology, Hypoxia and Degenerative Diseases to eliminate viruses and prolong lifespan using carbohydrate drug design. Bioxytran uses Galectin inhibitors to combat the virus, SARS-CoV-2. Glycovirology is a novel glycan-based platform technology. The concept involves using sugar-based drugs to block viruses. The company is developing an inventive platform of oxygen therapeutic treatments for hypoxic conditions and necrosis prevention.